The total return over the past 12 months is -71.87% vs. +16.94% for the S&P 500. So far it's up -48.26% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (71.87%) | (76.19%) | (79.33%) | (48.59%) | N/A | N/A |
| Total Return CAGR | (71.87%) | (76.19%) | (79.32%) | (48.59%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Processa Pharmaceuticals, Inc. (PCSA)
| Year | Start price | End price | PCSA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.88 | $1.49 | (48.26%) | +14.51% | (62.77%) |
| 2025 | $22.10 | $2.88 | (86.97%) | +17.72% | (104.69%) |
| 2024 | $167.25 | $22.10 | (86.79%) | +24.89% | (111.68%) |
| 2023 | $550.00 | $167.25 | (69.59%) | +26.19% | (95.78%) |
| 2022 | $2,450.00 | $550.00 | (77.55%) | (18.17%) | (59.38%) |
| 2021 | $3,297.50 | $2,450.00 | (25.70%) | +28.74% | (54.44%) |
| 2020 | $9,000.00 | $3,297.50 | (63.36%) | +18.37% | (81.73%) |
| 2019 | $12,600.00 | $9,000.00 | (28.57%) | +31.22% | (59.79%) |
| 2018 | $15,400.00 | $12,600.00 | (18.18%) | (4.56%) | (13.62%) |
| 2017 | $875.00 | $15,400.00 | +1660.00% | +21.70% | +1638.30% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
